Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRANSCEND NHL 001: Breyanzi in R/R B-cell NHL
NCT02631044Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Jan 2016
- Primary completion
- May 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CD19-targeted CAR T cells in diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), follicular lymphoma (FL) and 1 more (2 arms), sponsored by Celgene Corporation. Primary endpoints: Treatment-related adverse events up to 730 days, Dose-limiting toxicities at 28 days and 1 more. Started Jan 2016; status: completed.
02
Drugs
CD19-targeted CAR T cells
03
Conditions
diffuse large B-cell lymphoma (DLBCL)primary mediastinal large B-cell lymphoma (PMBCL)follicular lymphoma (FL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT02631044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02631044.